CORRELATION OF LOW HDL AND HIGH LDL-C LEVELS WITH SEVERITY OF CORONARY ARTERY DISEASE ON CORONARY ANGIOGRAM

Main Article Content

Sher Wali Khan
Ayesha Fayyaz
Ikram Ullah
Usman Ahmad
Maheen Sheikh
Syed Muhammad Nayab Ali

Keywords

cardiovascular risk, dyslipidemia, genuine score, coronary angiography, LDL-C, coronary artery disease

Abstract

Background


Coronary artery disease (CAD) is the most common cause of death worldwide. CAD pathophysiology and development are strongly linked to lipid profile, especially HDL and LDL-C.


Objective


To study the effect of low HDL and high LDL-C levels on coronary artery disease severity in coronary angiography patients


Material and Methods


A descriptive comparative study with 300 coronary artery patients was planned, dividing samples into Group A (low HDL and high LDL-C) and Group B (normal HDL and LDL-C). The Gensini score evaluated coronary lesion severity based on luminal narrowing and location.


Results


Group A had a considerably higher mean Gensini score (p < 0.05) than Group B. 97 patients (64.6%) in Group A had severe CAD (Gensini score >20), compared to 51 (34%) in Group B, 34 patients (22.7%) in Group A and 60 patients (40%) in Group B had moderate CAD (Gensini score 11-20). Mild CAD (Gensini score ≤10) was seen in 19 patients (12.7%) in Group A and 39 patients (26%) in Group B, reporting a significant difference between groups (p<0.01). The correlation test found that the severity of CAD is significantly associated with diabetes and hypertension. Regression analysis found a positive association between severe CAD and LDL-C levels (P<0.05).


Conclusion


The study found a strong association between low HDL and high LDL-C levels and coronary angiography severity. CAD was more common and severe in patients with low HDL and high LDL-C. The severity of CAD was found to be associated with diabetes and hypertension.

Abstract 36 | pdf Downloads 7

References

Shao C, Wang J, Tian J, Tang YD: Coronary artery disease: from mechanism to clinical practice. Coronary Artery Disease: Therapeutics and Drug Discovery. 2020, 1:36. 10.1007/978-981-15-2517-9_1
2. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacological reviews. 2016, 1:342-74. 10.1124/pr.58.3.1
3. Jun JE, Choi YJ, Lee YH, et al.: ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL-C cholesterol levels. Korean journal of internal medicine. 2018, 33:138. 10.3904/kjim.2017.396
4. Sampson UK, Fazio S, Linton MF: Residual cardiovascular risk despite optimal LDL-C cholesterol reduction with statins: the evidence, aetiology, and therapeutic challenges. Current atherosclerosis reports. 2012, 14:1-0. 10.1007/s11883-011-0219-7
5. Farmer JA, Liao J: Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis. Current atherosclerosis reports. 2011, 13:107-14. 10.1007/s11883-011-0166-3
6. Cobble M, Bale B: Carotid intima-media thickness: knowledge and application to everyday practice. Postgrad Med. 2010, 122:10-8. 10.3810/pgm.2010.01.2091
7. Meijboom WB, Van Mieghem CA, van Pelt N, et al.: Comprehensive assessment of coronary artery stenoses: computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. Journal of the American College of Cardiology. 2008, 52:636-43. 10.1016/j.jacc.2008.05.024
8. Grobbee DE, Bots ML: Atherosclerotic disease regression with statins: studies using vascular markers. International journal of cardiology. 2004, 96:447-59. 10.1016/j.ijcard.2004.01.005
9. Sanin V, Pfetsch V, Koenig W: Dyslipidemias and cardiovascular prevention: tailoring treatment according to lipid phenotype. Current cardiology reports. 2017, 19:1-3. 10.1007/s11886-017-0869-3
10. Jalali, M.T., Honomaror, et al.: Reference Ranges for Serum Total Cholesterol, HDL-Cholesterol, LDL-C- Cholesterol, and VLDL-C-Cholesterol and Triglycerides in Healthy Iranian Ahvaz Population. Ind J Clin Biochem. 2013, 28:277-282. 10.1007/s12291-012-0268-x
11. Castelli WP: Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol. 1988, 4:5.
12. Yusuf S, Hawken S, Ounpuu S, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004, 364:937-52. 10.1016/s0140-6736(04)17018-9
13. Hajar R: Risk factors for coronary artery disease: historical perspectives. Heart Views: the official journal of the Gulf Heart Association. 2017, 18:109. 10.4103/heart views.heartviews_106_17
14. Vishram JK: Prognostic interactions between cardiovascular risk factors. Dan Med J. 2014, 61:4892.
15. Saeidifard F, Medina-Inojosa JR, Supervia M, et al.: The Effect of Replacing Sitting With Standing on Cardiovascular Risk Factors: A Systematic Review and Meta-analysis. Mayo Clin Proc Innov Qual Outcomes. 2020, 1:611-626. 10.1016/j.mayocpiqo.2020.07.017
16. Bonilha I, Luchiari B, Nadruz W, Sposito AC: Very low HDL levels: clinical assessment and management. Arch Endocrinol Metab. 2023, 18:3-18. 10.20945/2359-3997000000585
17. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110:227-39. 10.1161/01.cir.0000133317.49796.0e
18. Miller M, Stone NJ, Ballantyne C, et al.: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011, 123:2292-333. 10.1161/cir.0b013e3182160726
19. Tashiro K, Inoue H, Shiga Y, et al.: Associations Between High Levels of High-Density Lipoprotein Cholesterol and the Presence and Severity of Coronary Artery Disease in Patients Who Have Undergone Coronary Computed Tomography Angiography. J Clin Med Res. 2020, 12:734-739. 10.14740/jocmr4367
20. Carmo MM, Rui Cruz Ferreira RC: Does metabolic syndrome predict significant angiographic coronary artery disease? Revista Portuguesa de Cardiologia, December. 2012, 3:769-778. 10.1016/j.repc.2012.03.006
21. Barter P, Gotto AM, LaRosa JC, et al.: HDL cholesterol, deficient levels of LDL-C cholesterol, and cardiovascular events. N Engl J Med. 2007, 1301-10. 10.1056/nejmoa064278
22. Savel J, Lafitte M, Pucheu Y, et al.: Very low HDL cholesterol levels and atherosclerosis, a variable relationship--a review of LCAT deficiency. Vasc Health Risk Manag. 2012, 8:357-61. 10.2147/vhrm.s29985
23. Chávez Fernández JA, Ramírez Mendoza M, Kassck Ipinaa H, et al.: The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study. PLoS One. 2023, 25:0290544. 10.1371/journal.pone.0290544
24. Mørland JG, Magnus P, Vollset SE, et al.: Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345 000 men and women aged 20-79 years. Int J Epidemiol. 20232, 52:1257-1267. 10.1093/ije/dyad011
25. Muhlestein JB, Lappé DL, Lima JA, et al.: Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomised clinical trial. Jama. 2014, 3:2234-43. 10.1001/jama.2014.15825
26. Staef M, Ott C, Kannenkeril D, et al.: Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross-sectional analysis. Sci Rep. 20232, 13:8944. 10.1038/s41598-023-35589-4